Gabapentin Tablet
Product Images NDC 68071-2214

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2214). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2214 9)

This appears to be a description of a medication, specifically Gabapentin 800mg tablets in a bottle of 90, with Lot # 000000 and NDC # 68071-2214-09. The tablets are white or off-white and scored on both sides. The bottle has an expiration date of 00-00 and is to be stored at a controlled temperature between 59-86°F. The manufacturer's NDC is 50228-178-05 and the tablet is serial number 00000000002 with a Product # P1293090. There is a warning to keep the medication out of reach of children and to contact 1-800-FDA-1083 in case of adverse reactions.*

FDA Label Image

Figure 1 (Image 01)

This appears to be a chart or table displaying the mean pain score for two groups - one group receiving a fixed dose of medication called "Parkod" and another group receiving a high dose of Gabapentin. The table also displays the time period for the study, with baseline and several weeks indicated. Not enough information is provided to understand the context or purpose of the study.*

FDA Label Image

Figure 2 (Image 02)

This appears to be a chart or graph showing the results of a study on the effects of Gabapentin on pain score over a 4-week fixed dose period. The study has a placebo group and two Gabapentin groups: one taking 1800 mg/day and the other taking 2400 mg/day. The pain score is measured on a scale of 0-10 and is shown to decrease over the duration of the study in both Gabapentin groups compared to the placebo group. However, without further context or information, it is difficult to fully understand the purpose and conclusions of the study.*

FDA Label Image

Figure 3 (Image 03)

FDA Label Image

Cockcroft And Gault Equation (Image 04)

FDA Label Image

Gabapentin Structural Formula (Image 05)

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.